[{"from": "human", "value": "Provide a description of this molecule. [C][C][C][S][C][=N][C][=Branch2][Ring1][S][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][Branch1][Branch1][N][=N][Ring1][=Branch1][C@@H1][C][C@@H1][Branch1][=Branch2][C@H1][Branch1][Branch1][C@H1][Ring1][Branch1][O][O][O][C][C][O][N][C@@H1][C][C@H1][Ring1][Ring1][C][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][F]"}, {"from": "gpt", "value": "The molecule is an ADP derivative developed for its P2Y12 receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.  Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011."}]